CN113456810A - 一种新型抗新冠病毒治疗性疫苗及其制备方法和应用 - Google Patents

一种新型抗新冠病毒治疗性疫苗及其制备方法和应用 Download PDF

Info

Publication number
CN113456810A
CN113456810A CN202010237511.0A CN202010237511A CN113456810A CN 113456810 A CN113456810 A CN 113456810A CN 202010237511 A CN202010237511 A CN 202010237511A CN 113456810 A CN113456810 A CN 113456810A
Authority
CN
China
Prior art keywords
protein
immune
recombinant
new coronavirus
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010237511.0A
Other languages
English (en)
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Xing'ao Biological Technology Co ltd
Original Assignee
Hangzhou Xing'ao Biological Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Xing'ao Biological Technology Co ltd filed Critical Hangzhou Xing'ao Biological Technology Co ltd
Priority to CN202010237511.0A priority Critical patent/CN113456810A/zh
Priority to PCT/CN2020/142585 priority patent/WO2021196808A1/fr
Publication of CN113456810A publication Critical patent/CN113456810A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN202010237511.0A 2020-03-30 2020-03-30 一种新型抗新冠病毒治疗性疫苗及其制备方法和应用 Pending CN113456810A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202010237511.0A CN113456810A (zh) 2020-03-30 2020-03-30 一种新型抗新冠病毒治疗性疫苗及其制备方法和应用
PCT/CN2020/142585 WO2021196808A1 (fr) 2020-03-30 2020-12-31 Nouveau vaccin thérapeutique contre le nouveau coronavirus, son procédé de préparation et son utilisation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010237511.0A CN113456810A (zh) 2020-03-30 2020-03-30 一种新型抗新冠病毒治疗性疫苗及其制备方法和应用

Publications (1)

Publication Number Publication Date
CN113456810A true CN113456810A (zh) 2021-10-01

Family

ID=77866027

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010237511.0A Pending CN113456810A (zh) 2020-03-30 2020-03-30 一种新型抗新冠病毒治疗性疫苗及其制备方法和应用

Country Status (2)

Country Link
CN (1) CN113456810A (fr)
WO (1) WO2021196808A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111956797A (zh) * 2020-07-10 2020-11-20 清华大学 新型疫苗佐剂及其在新冠肺炎疫苗和其他疫苗中的应用
CN114470186A (zh) * 2022-02-17 2022-05-13 唐颐控股(深圳)有限公司 一种可吸入式纳米新冠疫苗的制备方法
CN115417906A (zh) * 2022-09-14 2022-12-02 杭州星鳌生物科技有限公司 环二核苷酸金属化合物及其制备方法、应用
CN115969969A (zh) * 2023-02-13 2023-04-18 中国科学院长春应用化学研究所 一种仿病毒结构纳米颗粒疫苗及其制备方法和应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114344457B (zh) * 2021-11-13 2024-01-12 暨南大学 新型冠状病毒蛋白质抗原纳米疫苗及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106540256A (zh) * 2016-03-27 2017-03-29 聊城市奥润生物医药科技有限公司 环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用
CN108997497A (zh) * 2018-03-30 2018-12-14 苏州思坦维生物技术股份有限公司 特异结合人质膜膜泡关联蛋白pv-1的单克隆抗体及其制备方法与应用
WO2019126356A1 (fr) * 2017-12-19 2019-06-27 The University Of North Carolina At Chapel Hill Procédés et compositions pour l'administration de vecteurs viraux à travers la barrière hémato-encéphalique

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101007168B (zh) * 2006-01-23 2010-06-09 北京大学 一种sars疫苗及其制备方法
CA2898130A1 (fr) * 2013-03-15 2014-09-18 The Trustees Of The University Of Pennsylvania Vaccins comprenant des adjuvants biomoleculaires
WO2017120576A1 (fr) * 2016-01-07 2017-07-13 Duke University Vaccins contre le cancer et méthodes d'administration
US10813988B2 (en) * 2016-02-16 2020-10-27 President And Fellows Of Harvard College Pathogen vaccines and methods of producing and using the same
SG11201807960PA (en) * 2016-03-16 2018-10-30 Inst Curie Method for preparing viral particles with cyclic dinucleotide and use of said particles for treating cancer
CN110167566A (zh) * 2016-12-21 2019-08-23 弗莱德哈钦森癌症研究中心 治疗实体瘤细胞和逃避变体的支架
IL302880A (en) * 2017-04-04 2023-07-01 Avidea Tech Inc Peptide-based ingredients, production methods, and their uses for inducing an immune response
CN108310378A (zh) * 2018-04-28 2018-07-24 杭州星鳌生物科技有限公司 一类新型免疫联体抗肿瘤创新药物的制备及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106540256A (zh) * 2016-03-27 2017-03-29 聊城市奥润生物医药科技有限公司 环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用
WO2019126356A1 (fr) * 2017-12-19 2019-06-27 The University Of North Carolina At Chapel Hill Procédés et compositions pour l'administration de vecteurs viraux à travers la barrière hémato-encéphalique
CN108997497A (zh) * 2018-03-30 2018-12-14 苏州思坦维生物技术股份有限公司 特异结合人质膜膜泡关联蛋白pv-1的单克隆抗体及其制备方法与应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
夏立秋等: "新型冠状病毒SARS-CoV-2研究进展", 《激光生物学报》 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111956797A (zh) * 2020-07-10 2020-11-20 清华大学 新型疫苗佐剂及其在新冠肺炎疫苗和其他疫苗中的应用
CN114470186A (zh) * 2022-02-17 2022-05-13 唐颐控股(深圳)有限公司 一种可吸入式纳米新冠疫苗的制备方法
CN114470186B (zh) * 2022-02-17 2023-10-20 唐颐控股(深圳)有限公司 一种可吸入式纳米新冠疫苗的制备方法
CN115417906A (zh) * 2022-09-14 2022-12-02 杭州星鳌生物科技有限公司 环二核苷酸金属化合物及其制备方法、应用
CN115417906B (zh) * 2022-09-14 2024-02-27 杭州星鳌生物科技有限公司 环二核苷酸金属化合物及其制备方法、应用
WO2024055758A1 (fr) * 2022-09-14 2024-03-21 杭州星鳌生物科技有限公司 Composé métallique dinucléotidique cyclique, son procédé de préparation et son utilisation
CN115969969A (zh) * 2023-02-13 2023-04-18 中国科学院长春应用化学研究所 一种仿病毒结构纳米颗粒疫苗及其制备方法和应用

Also Published As

Publication number Publication date
WO2021196808A1 (fr) 2021-10-07

Similar Documents

Publication Publication Date Title
CN113456810A (zh) 一种新型抗新冠病毒治疗性疫苗及其制备方法和应用
US6355271B1 (en) Therapeutic calcium phosphate particles and methods of manufacture and use
EP0812209B1 (fr) Vehicles cochleaires utilises dans l'administration de molecules biologiquement utiles
US9149441B2 (en) Nanospheres encapsulating bioactive material and method for formulation of nanospheres
US20080311214A1 (en) Polymerized solid lipid nanoparticles for oral or mucosal delivery of therapeutic proteins and peptides
Wu et al. CASTING: a potent Supramolecular Strategy to cytosolically deliver STING agonist for Cancer Immunotherapy and SARS-CoV-2 vaccination
EP1418939A2 (fr) Particules de phosphate de calcium utilisees comme adjuvants pour la muqueuse
CN105873941A (zh) 生存素导向的癌症疫苗治疗
WO2018183901A1 (fr) Composition vaccinale d'acide nucléique comprenant une formulation lipidique, et procédé permettant d'augmenter l'efficacité de vaccins d'acide nucléique
WO2023051701A1 (fr) Arnm, protéine et vaccin contre l'infection par sars-cov-2
US10786558B2 (en) Oral dissolving films
US11252957B2 (en) Nucleic acid-peptide capsule complexes
EP1420065A1 (fr) Procede de production d'enveloppes virales inactivees
KR20160132044A (ko) 효모 세포벽 입자를 사용하는 백신 전달 시스템
CN110327314B (zh) 一种可气溶胶化的A型肉毒毒素AHc亚单位疫苗干粉吸入剂
CN111840538A (zh) 一种水痘-带状疱疹病毒亚单位纳米疫苗的制备方法和应用
WO2021253807A1 (fr) Complexe anti-coronavirus et son procédé de préparation
WO2010089940A1 (fr) Vaccin mucosique
US20240261387A1 (en) Respiratory syncytial virus mrna vaccine
WO2024131862A1 (fr) Vaccin contre le vrs ainsi que sa méthode de préparation et son utilisation
Hou Lipid Nanoparticle-Messenger RNA Formulations against Infections
Ziqi et al. Nanotechnology-facilitated vaccine development during the coronavirus disease(COVID-) pandemic
EP1471034A2 (fr) Particules thérapeutiques de phosphate de calcium et procédés de fabrication et d'utilisation
JP5685562B2 (ja) らい菌による感染症を予防又は治療するためのワクチン、抗体及び医薬
JP5086633B2 (ja) 細胞内に侵入する能力を有するペプチド及び核酸、物質を細胞内に侵入させるための物質移送用剤及び物質移送方法、並びに、らい菌による感染症を予防又は治療するためのワクチン、抗体及び医薬

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination